ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC)
Xu, R.-H., Gomes, D. B. D., Chen, J.-S., Lordick, F., Paulson, A. S., Rha, S. Y., Tabernero, J., Yamaguchi, K., … Read More
